American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004

被引：637

作者：

Winer, EP ^{[1
]}

Hudis, C ^{[1
]}

Burstein, HJ ^{[1
]}

Wolff, AC ^{[1
]}

Pritchard, KI ^{[1
]}

Ingle, JN ^{[1
]}

Chlebowski, RT ^{[1
]}

Gelber, R ^{[1
]}

Edge, SB ^{[1
]}

Gralow, J ^{[1
]}

Cobleigh, MA ^{[1
]}

Mamounas, EP ^{[1
]}

Goldstein, LJ ^{[1
]}

Whelan, TJ ^{[1
]}

Powles, TJ ^{[1
]}

Bryant, J ^{[1
]}

Perkins, C ^{[1
]}

Perotti, J ^{[1
]}

Braun, S ^{[1
]}

Langer, AS ^{[1
]}

Browman, GP ^{[1
]}

Somerfield, MR ^{[1
]}

机构：

[1] Amer Soc Clin Oncol, Canc Policy & Clin Affairs, Alexandria, VA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 03期

关键词：

D O I：

10.1200/JCO.2005.09.121

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose To update the 2003 American Society of Clinical Oncology technology assessment on adjuvant use of aromatase inhibitors. Recommendations Based on results from multiple large randomized trials, adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer should include an aromatase inhibitor in order to lower the risk of tumor recurrence. Neither the optimal timing nor duration of aromatase inhibitor therapy is established. Aromatase inhibitors are appropriate as initial treatment for women with contra indications to tamoxifen. For all other postmenopausal women, treatment options include 5 years of aromatase inhibitors treatment or sequential therapy consisting of tamoxifen (for either 2 to 3 years or 5 years) followed by aromatase inhibitors for 2 to 3, or 5 years. Patients intolerant of aromatase inhibitors should receive tamoxifen. There are no data on the use of tamoxifen after an aromatase inhibitor in the adjuvant setting. Women with hormone receptor-negative tumors should not receive adjuvant endocrine therapy. The role of other biomarkers such as progesterone receptor and HER2 status in selecting optimal endocrine therapy remains controversial. Aromatase inhibitors are contraindicated in premenopausal women; there are limited data concerning their role in women with treatment-related amenorrhea. The side effect profiles of tamoxifen and aromatase inhibitors differ. The late consequences of aromatase inhibitor therapy, including osteoporosis, are not well characterized. Conclusion The Panel believes that optimal adjuvant hormonal therapy for a postmenopausal woman with receptor-positive breast cancer includes an aromatase inhibitor as initial therapy or after treatment with tamoxifen. Women with breast cancer and their physicians must weigh the risks and benefits of all therapeutic options. (C) 2005 by American Society of Clinical Oncology.

引用

页码：619 / 629

页数：11

共 50 条

[1]

[Anonymous], 1998, LANCET, V351, P1451

[2]

Baum M, 2002, LANCET, V359, P2131

[3]

Baum M, 2003, Cancer, V98, P1802

[4]

BAUM M, 2001, BREAST CANC RES TREA, V69

[5] Screening for osteoporosis in postmenopausal women: Recommendations and rationale [J].

Berg, AO ;

Allan, JD ;

Frame, PS ;

Homer, CJ ;

Johnson, MS ;

Klein, JD ;

Lieu, TA ;

Mulrow, CD ;

Orleans, CT ;

Peipert, JF ;

Pender, NJ ;

Siu, AL ;

Teutsch, SM ;

Westhoff, C ;

Woolf, SH .

ANNALS OF INTERNAL MEDICINE, 2002, 137 (06) :526-528

[6]

BOCCARDO F, 2003, BREAST CANC RES TREA, V82

[7]

Bonneterre J, 2001, CANCER, V92, P2247, DOI 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO

[8]

2-Y

[9]

BRAVERMAN AS, 2002, P AN M AM SOC CLIN, V21, P42

[10] Primary care - Primary care for survivors of breast cancer [J].

Burstein, HJ ;

Winer, EP .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (15) :1086-1094

← 1 2 3 4 5 →